WO2003020320A3 - Nanopartikel mit daran immobilisiertem biologisch aktivem tnf - Google Patents

Nanopartikel mit daran immobilisiertem biologisch aktivem tnf Download PDF

Info

Publication number
WO2003020320A3
WO2003020320A3 PCT/EP2002/009185 EP0209185W WO03020320A3 WO 2003020320 A3 WO2003020320 A3 WO 2003020320A3 EP 0209185 W EP0209185 W EP 0209185W WO 03020320 A3 WO03020320 A3 WO 03020320A3
Authority
WO
WIPO (PCT)
Prior art keywords
nanoparticles
tnf
cytokine
immobilised
same
Prior art date
Application number
PCT/EP2002/009185
Other languages
English (en)
French (fr)
Other versions
WO2003020320A2 (de
Inventor
Guenter Tovar
Thomas Schiestel
Herwig Brunner
Klaus Pfizenmaier
Matthias Grell
Peter Scheurich
Angela Hammer
Original Assignee
Fraunhofer Ges Forschung
Guenter Tovar
Thomas Schiestel
Herwig Brunner
Klaus Pfizenmaier
Matthias Grell
Peter Scheurich
Angela Hammer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fraunhofer Ges Forschung, Guenter Tovar, Thomas Schiestel, Herwig Brunner, Klaus Pfizenmaier, Matthias Grell, Peter Scheurich, Angela Hammer filed Critical Fraunhofer Ges Forschung
Priority to AU2002333444A priority Critical patent/AU2002333444A1/en
Priority to CA002458682A priority patent/CA2458682A1/en
Priority to US10/488,374 priority patent/US7368295B2/en
Priority to JP2003524625A priority patent/JP2005504066A/ja
Priority to EP02797581A priority patent/EP1425306A2/de
Publication of WO2003020320A2 publication Critical patent/WO2003020320A2/de
Publication of WO2003020320A3 publication Critical patent/WO2003020320A3/de

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6933—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained by reactions only involving carbon to carbon, e.g. poly(meth)acrylate, polystyrene, polyvinylpyrrolidone or polyvinylalcohol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/06—Peptides being immobilised on, or in, an organic carrier attached to the carrier via a bridging agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Ceramic Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Die vorliegende Erfindung betrifft Nanopartikel mit daran immobilisiertem Tumor-Nekrose-Faktor (TNF) oder Cytokin, wobei TNF oder das Cytokin vorzugs- weise in Form eines Trimers gerichtet und unter Beibehaltung seiner biologischen Aktivität am Träger immobilisiert ist, Verfahren zur gerichteten Immobilisierung von TNF oder Cytokin an Nanopartikeln, die Verwendung der immobilisierten TNF oder Cytokin aufweisenden Nanopartikel zur Identifizierung und/oder Isolierung von Cytokinoder TNF- Bindungspartnern sowie zur Identifizierung und/oder Isolierung von Hemmstoffen der Interaktion zwischen TNF oder Cytokin und seinen Bindungspartnern, die Verwendung derartiger Nanopartikel zur Herstellung einer pharmazeutischen Zusammensetzung, insbesondere zur Therapie von Tumoren, sowie pharmazeutische und diagnostische Zusammensetzungen, die derartige Nanopartikel enthalten.
PCT/EP2002/009185 2001-08-31 2002-08-16 Nanopartikel mit daran immobilisiertem biologisch aktivem tnf WO2003020320A2 (de)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2002333444A AU2002333444A1 (en) 2001-08-31 2002-08-16 Nanoparticles comprising biologically active tnf which is immobilised on the same
CA002458682A CA2458682A1 (en) 2001-08-31 2002-08-16 Nanoparticles comprising biologically active tnf which is immobilised on the same
US10/488,374 US7368295B2 (en) 2001-08-31 2002-08-16 Nanoparticles comprising biologically active TNF which is immobilized on the same
JP2003524625A JP2005504066A (ja) 2001-08-31 2002-08-16 表面に固定化された生物学的に活性なｔｎｆを有するナノ粒子
EP02797581A EP1425306A2 (de) 2001-08-31 2002-08-16 Nanopartikel mit daran immobilisiertem biologisch aktivem tnf

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10144252.1 2001-08-31
DE10144252A DE10144252A1 (de) 2001-08-31 2001-08-31 Nanopartikel mit daran immobilisiertem biologisch aktivem TNF

Publications (2)

Publication Number Publication Date
WO2003020320A2 WO2003020320A2 (de) 2003-03-13
WO2003020320A3 true WO2003020320A3 (de) 2003-10-30

Family

ID=7698300

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/009185 WO2003020320A2 (de) 2001-08-31 2002-08-16 Nanopartikel mit daran immobilisiertem biologisch aktivem tnf

Country Status (7)

Country Link
US (1) US7368295B2 (de)
EP (1) EP1425306A2 (de)
JP (1) JP2005504066A (de)
AU (1) AU2002333444A1 (de)
CA (1) CA2458682A1 (de)
DE (1) DE10144252A1 (de)
WO (1) WO2003020320A2 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110063939B (zh) * 2019-06-11 2021-08-17 邢更彦 冲击波介导释放的空心羟基磷灰石载药颗粒及其制备方法

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8197430B1 (en) * 1998-05-22 2012-06-12 Biopheresis Technologies, Inc. Method and system to remove cytokine inhibitor in patients
US6620382B1 (en) 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
CN1812766A (zh) * 2003-04-25 2006-08-02 宾州研究基金会 用于全身传递使生长停滞的、衍生于脂质的生物活性化合物的方法和系统
ES2347564T3 (es) * 2003-08-05 2010-11-02 Becton, Dickinson And Company Dispositivo y metodos para la recogida de una muestra de fluido biologico y el tratmaiento de componentes seleccionados.
DE102004014983A1 (de) 2004-03-26 2005-10-20 Univ Stuttgart Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
US9549895B2 (en) * 2004-04-23 2017-01-24 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving the viability of photoreceptor cells
WO2005107802A2 (en) * 2004-04-30 2005-11-17 Biopheresis Technologies, Llc Method and system to remove soluble tnfr1, tnfr2, and il2 in patients
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
US20090014682A1 (en) * 2005-05-20 2009-01-15 Jsr Corporation Carrier Polymer Particle, Process for Producing the Same, Magnetic Particle for Specific Trapping, and Process for Producing the Same
US7592330B2 (en) * 2005-08-08 2009-09-22 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving the viability of photoreceptor cells
US20070065514A1 (en) * 2005-09-22 2007-03-22 Howell Mark D Method for enhancing immune responses in mammals
US20090253613A1 (en) * 2006-01-04 2009-10-08 Do-Coop Technologies Ltd. Solid-Fluid Composition
JP2007297322A (ja) * 2006-04-28 2007-11-15 Toyobo Co Ltd サイトカイン産生の促進方法
US20100034808A1 (en) * 2006-11-21 2010-02-11 Toru Nakazawa Compositions and methods for preserving cells of the eye
FI20070174A0 (fi) * 2007-02-28 2007-02-28 Delsitech Oy Menetelmä silikakoostumusten valmistamiseksi, silikakoostumukset ja niiden käytöt
CN101678090B (zh) * 2007-03-07 2012-04-11 乌第有限合伙公司 用于预防和治疗自身免疫病的组合物和方法
US20100209946A1 (en) * 2007-04-19 2010-08-19 Naiyong Jing Uses of water-dispersible silica nanoparticles for attaching biomolecules
WO2008131063A1 (en) * 2007-04-19 2008-10-30 3M Innovative Properties Company Methods of use of solid support material for binding biomolecules
DE102007020302B4 (de) * 2007-04-20 2012-03-22 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verbesserte dreidimensionale biokompatible Gerüststruktur, die Nanopartikel beinhaltet
US9295736B2 (en) 2007-09-24 2016-03-29 Bar Ilan University Polymer nanoparticles coated by magnetic metal oxide and uses thereof
DE102009032658A1 (de) * 2009-07-09 2011-01-13 Forschungszentrum Jülich GmbH Mischung amphipathischer Moleküle und Verfahren zur Zellmembranmodifikation durch Fusion
US9937128B2 (en) 2009-08-03 2018-04-10 The University Of North Carolina At Chapel Hill Liposomes comprising a calcium phosphate-containing precipitate
GB0914446D0 (en) 2009-08-18 2009-09-30 King S College London Bioconjugates and their uses in imaging
SE535087C2 (sv) 2010-08-24 2012-04-10 En metod för att preparera en plan yta med en kontrollerad täthetsgradient av deponerade partiklar i nanostorlek
CN101966344B (zh) * 2010-10-29 2012-04-11 中国科学院上海硅酸盐研究所 一种具有磁性和发光性能的中空核壳纳米介孔载药体系及其制备与应用
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
KR20140022904A (ko) * 2011-04-20 2014-02-25 유니버시티 오브 시드니 치료방법 및 그에 사용가능한 제제
CN109116033A (zh) 2012-03-06 2019-01-01 塞莱克特生物疗法有限公司 用于选择抗细胞凋亡信号传导细胞的装置和方法及其用途
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
CA2932532C (en) 2012-12-04 2021-06-22 Phosphorex, Inc. Microparticles and nanoparticles having negative surface charges
JP2017500285A (ja) 2013-11-04 2017-01-05 ユーティーアイ リミテッド パートナーシップ 持続的免疫療法のための方法および組成物
US11299528B2 (en) 2014-03-11 2022-04-12 D&D Pharmatech Inc. Long acting TRAIL receptor agonists for treatment of autoimmune diseases
US11111284B2 (en) 2014-08-21 2021-09-07 The General Hospital Corporation Tumor necrosis factor superfamily and TNF-like ligand muteins and methods of preparing
BR112017006552A2 (pt) 2014-10-03 2017-12-19 Ntercept Llc composições e métodos para inibir a atividade biológica de biomoléculas solúveis
US12011480B2 (en) 2015-05-06 2024-06-18 Uti Limited Partnership Nanoparticle compositions for sustained therapy
AU2016285868B2 (en) * 2015-06-30 2021-11-11 Nanotics, Llc Compositions and methods related to scavenger particles
EA201890391A1 (ru) * 2015-07-29 2018-08-31 НАНОТИКС, ЭлЭлСи Модульные композиции для утилизации растворимых биомолекул и связанные с этим способы
CA3008392C (en) 2015-12-17 2021-11-09 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
WO2017176762A1 (en) 2016-04-06 2017-10-12 Nanotics, Llc Particles comprising subparticles or nucleic acid scaffolds
CA3020339C (en) 2016-04-07 2022-05-03 The Johns Hopkins University Compositions and methods for treating pancreatitis and pain with death receptor agonists
CN106344539B (zh) * 2016-08-25 2019-01-29 湖北大学 一种多功能靶向纳米胶囊抗癌药物的制备方法
EP3565604A4 (de) 2017-01-04 2020-09-09 Nanotics, LLC Verfahren zur anordnung von spülpartikeln
RU2691938C1 (ru) * 2018-06-15 2019-06-19 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) Противоопухолевое средство на основе биодеградируемых наночастиц, несущих рекомбинантный фактор некроза опухоли альфа человека
US20230331811A1 (en) * 2020-04-27 2023-10-19 CCOA Therapeutics Inc. Immobilized self-assembled protein multimers
US11767353B2 (en) 2020-06-05 2023-09-26 Theraly Fibrosis, Inc. Trail compositions with reduced immunogenicity
US11224858B1 (en) 2020-10-01 2022-01-18 Immunicom, Inc. Reduced leaching of a ligand
JP2023544347A (ja) * 2020-10-01 2023-10-23 イミューニコム， インコーポレイテッド リガンドの浸出の低減

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0247860A2 (de) * 1986-05-29 1987-12-02 Cetus Oncology Corporation Tumor-Nekrose-Faktor-Formulierung und ihre Herstellung
WO1990009798A1 (en) * 1989-02-24 1990-09-07 Immunotherapeutics, Inc. Immobilized cytokines
WO1993012142A1 (en) * 1991-12-10 1993-06-24 Tanox Biosystems, Inc. Cytokines with an unpaired cysteine residue and conjugates thereof
WO1999062535A2 (en) * 1998-06-01 1999-12-09 University Of Maryland Biotechnology Institute Receptor ligand antagonist complexes and their use in treating or preventing receptor mediated diseases
US6274552B1 (en) * 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
DE10045592A1 (de) * 2000-09-15 2002-03-28 Klaus Pfizenmaier Ein Antikörper-TNF-TNF Inhibitor Fusionsprotein (TNF-Selektokin) als zielspezifisches Prozytokin zur Tumortherapie

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003012071A2 (en) * 2001-08-03 2003-02-13 Elitra Pharmaceuticals, Inc. Nucleic acids of aspergillus fumigatus encoding industrial enzymes and methods of use

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0247860A2 (de) * 1986-05-29 1987-12-02 Cetus Oncology Corporation Tumor-Nekrose-Faktor-Formulierung und ihre Herstellung
WO1990009798A1 (en) * 1989-02-24 1990-09-07 Immunotherapeutics, Inc. Immobilized cytokines
WO1993012142A1 (en) * 1991-12-10 1993-06-24 Tanox Biosystems, Inc. Cytokines with an unpaired cysteine residue and conjugates thereof
US6274552B1 (en) * 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
WO1999062535A2 (en) * 1998-06-01 1999-12-09 University Of Maryland Biotechnology Institute Receptor ligand antagonist complexes and their use in treating or preventing receptor mediated diseases
DE10045592A1 (de) * 2000-09-15 2002-03-28 Klaus Pfizenmaier Ein Antikörper-TNF-TNF Inhibitor Fusionsprotein (TNF-Selektokin) als zielspezifisches Prozytokin zur Tumortherapie

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
FASSINA G ET AL: "Binding of human tumor necrosis factor alpha to multimeric complementary peptides.", ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS. UNITED STATES JUL 1992, vol. 296, no. 1, July 1992 (1992-07-01), pages 137 - 143, XP009003847, ISSN: 0003-9861 *
KAINULAINEN VARPU ET AL: "Suppression of syndecan-1 expression in endothelial cells by tumor necrosis factor-alpha.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 31, 1996, pages 18759 - 18766, XP002231936, ISSN: 0021-9258 *
KAMADA HARUHIKO ET AL: "Antitumor activity of tumor necrosis factor-alpha conjugated with polyvinylpyrrolidone on solid tumors in mice.", CANCER RESEARCH, vol. 60, no. 22, 15 November 2000 (2000-11-15), pages 6416 - 6420, XP002231438, ISSN: 0008-5472 *
POSTMA N S ET AL: "Treatment with liposome-bound recombinant human tumor necrosis factor-alpha suppresses parasitemia and protects against Plasmodium berghei k173-induced experimental cerebral malaria in mice.", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 288, no. 1, January 1999 (1999-01-01), pages 114 - 120, XP002231657, ISSN: 0022-3565 *
SAVVA MICHALAKIS ET AL: "A genetically modified recombinant tumor necrosis factor-alpha conjugated to the distal terminals of liposomal surface grafted polyethyleneglycol chains.", INTERNATIONAL JOURNAL OF PHARMACEUTICS (AMSTERDAM), vol. 184, no. 1, 5 July 1999 (1999-07-05), pages 45 - 51, XP001121142, ISSN: 0378-5173 *
SCHERF U ET AL: "CYTOTOXIC AND ANTITUMOR ACTIVITY OF A RECOMBINANT TUMOR NECROSIS FACTOR-B1(FV) FUSION PROTEIN ON LEY ANTIGEN-EXPRESSING HUMAN CANCER CELLS", CLINICAL CANCER RESEARCH, THE ASSOCIATION, DENVILLE, NJ, US, vol. 2, no. 9, 1 September 1996 (1996-09-01), pages 1523 - 1531, XP000653372, ISSN: 1078-0432 *
TSUNODA SHINICHI ET AL: "Enhanced antitumor potency of polyethylene glycolylated tumor necrosis factor-alpha: A novel polymer-conjugation technique with a reversible amino-protective reagent.", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 290, no. 1, July 1999 (1999-07-01), pages 368 - 372, XP002231935, ISSN: 0022-3565 *
UTSUMI T ET AL: "Preparation and characterization of liposomal-lipophilic tumor necrosis factor.", CANCER RESEARCH. UNITED STATES 1 JUL 1991, vol. 51, no. 13, 1 July 1991 (1991-07-01), pages 3362 - 3366, XP001145748, ISSN: 0008-5472 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110063939B (zh) * 2019-06-11 2021-08-17 邢更彦 冲击波介导释放的空心羟基磷灰石载药颗粒及其制备方法

Also Published As

Publication number Publication date
WO2003020320A2 (de) 2003-03-13
CA2458682A1 (en) 2003-03-13
JP2005504066A (ja) 2005-02-10
DE10144252A1 (de) 2003-03-27
US7368295B2 (en) 2008-05-06
EP1425306A2 (de) 2004-06-09
AU2002333444A1 (en) 2003-03-18
US20040265392A1 (en) 2004-12-30

Similar Documents

Publication Publication Date Title
WO2003020320A3 (de) Nanopartikel mit daran immobilisiertem biologisch aktivem tnf
WO2003083041A3 (en) Cripto-specific antibodies
WO2003034803A3 (en) Methods for determining toxicity reversing agents
WO2003027248A8 (en) Antibody inhibitors of gdf-8 and uses thereof
ZA979550B (en) Method for the preparation of methylidene malonate nanoparticles, nanoparticles which optionally contain one or more biologically active molecules, and pharmaceutical compositions containing them.
DE60228721D1 (en) Zellproliferationsinhibitoren mit anti-glypican-3-antikörper
WO2002088170A3 (en) Cripto blocking antibodies and uses thereof
WO2004080425A3 (en) Polypeptide compounds for inhibiting angiogenesis and tumor growth
HK1062440A1 (en) Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
WO2005052001A3 (en) Anti-il-20 receptor antibodies and binding partners and methods of using in inflammation
WO2003099771A3 (en) Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
CA2366932A1 (en) Cyclic protein tyrosine kinase inhibitors
WO2003049702A8 (en) Vanilloid receptor ligands and their use in treatments
WO2003084539A3 (en) New pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
AU6379500A (en) Chemical mechanical polishing systems and methods for their use
WO2002098477A3 (en) Bioactive surface modifiers for polymers and articles made therefrom
WO2005025615A3 (en) FACTOR IXa SPECIFIC ANTIBODIES DISPLAYING FACTOR VIIIa LIKE ACTIVITY
DE60313004D1 (de) Alpha-7-nikotinsäure-rezeptoragonisten und statine in kombination
CA2533963A1 (en) Urea derivatives and the use thereof as inhibitors of tyrosine kinases
WO2003010291A3 (en) Treatment of immune disorders and b cell disorders
EP1466602A4 (de) Organfibroseinhibitoren
WO2003053474A3 (en) Use of micro-organisms for a directed delivery of substances to specific parts of the gut
EP2014291A3 (de) Piperazinon-Zusammensetzungen als tumor- und krebsbekämpfende Wirkstoffe und Behandlungsverfahren
WO1988008842A3 (fr) 2-ACYLPYRIDIN-alpha-(N)-HETARYLHYDRAZONES SUBSTITUEES ET MEDICAMENTS CONTENANT CELLES-CI
CA2384418A1 (en) Use of cytokines, cells, and mitogens to inhibit graft versus host disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DK DZ EC EE ES FI GB GD GE GH GM HR ID IL IN IS JP KE KG KP KR KZ LC LK LS LT LU LV MA MD MG MK MN MW MZ NO NZ OM PH PL PT RO RU SD SE SI SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002797581

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2458682

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003524625

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 10488374

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2002797581

Country of ref document: EP